Category Archives: Press Release

FDA authorizes Sylentis (PharmaMar Group) to initiate Phase III trial with tivanisiran for the treatment of dry eye disease

PharmaMar signs a new agreement with Adium to commercialize Zepzelca® (lurbinectedin) in Latin America

PharmaMar Group reports record results for 2020

PharmaMar enlarges its facilities to meet its upcoming business challenges

PharmaMar presents new data on Zepzelca® (lurbinectedin) in combination with irinotecan at an oral session at (rescheduled) IASLC 2020

GENOMICA, PharmaMar Group, announces that they have validated their PCR testing kit for saliva based sampling

PharmaMar will present new data for ZepzelcaTM (lurbinectedin) at rescheduled IASLC 2020

PharmaMar signs a licensing agreement with R-Pharm to commercialize Yondelis® in Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Uzbekistan, Turkmenistan, Ukraine and Georgia

PharmaMar and Jazz Pharmaceuticals announce results of the ATLANTIS phase III study with lurbinectedin